Research on how cancer spreads through the body. Covers metastasis monitoring, bone metastasis, and nanoparticle treatments.
Researchers at Winship Cancer Institute report that 2-methoxyestradiol (2ME2) inhibits tumor growth and angiogenesis by suppressing HIF. The compound targets microtubules, leading to the downregulation of HIF-1a and inhibition of tumor angiogenesis.
Researchers have identified a key function of merlin in maintaining adherens junctions, which are essential for suppressing cancer development and progression. The study reveals that loss of merlin results in destabilization of these junctions, leading to unchecked cell proliferation and tumor formation.
A new technique developed by Malins' laboratory uses Fourier transform-infrared spectroscopy to analyze DNA from prostate tumor biopsies, allowing doctors to identify patients at high risk for metastasis. This breakthrough enables more informed treatment decisions and potentially saves lives.
Researchers discovered a link between genetic markers and prostate cancer spread in African-American men. The study found that the ratio of MMP to E-cadherin accurately predicted cancer metastasis.
Researchers identified a specific gene required for liver cancer metastasis, which may serve as a diagnostic marker and therapeutic target. The study found that the activity of genes in tumors with metastatic potential differed from those without, enabling early detection and potentially improving treatment outcomes.
A new study identifies molecular predictors of breast cancer metastasis, including matriptase and HAI-1. The research may lead to a targeted way to treat cancers at risk of spreading, saving women from unnecessary chemotherapy.
Researchers have identified a gene responsible for the spread of cancer in the body, which could lead to more targeted and less toxic treatment options. The study found that silencing this gene can halt the migration of cancer cells, reducing the risk of metastasis.
Scientists at Thomas Jefferson University found that a bacterial toxin opens a cellular door, allowing calcium to flow into tumor cells, which slows cell division and may lead to new methods of treating colorectal cancer. The discovery could also enable the use of the toxin as an intravenous infusion to treat metastatic tumors.
Researchers found no difference in life expectancy between single- and multiple-fraction radiotherapy for painful bone metastases. Single-fraction radiotherapy is more cost-effective, with a lower treatment cost of $2,438 compared to $3,311 for multiple-fraction radiotherapy.
Researchers found a genetic 'signature' in some solid tumors that predicts their tendency to spread. This signature is present in early stages of cancer and can be detected at diagnosis, supporting the idea that primary tumors are pre-configured to metastasize.
Researchers have identified two compounds that inhibit PTHrP production, reducing metastatic bone breakdown and tumor burden. The findings suggest potential therapeutic benefits for treating both bone metastasis and hypercalcemia in breast cancer patients.
Researchers at UVA have identified a gene called RhoGDI2 that plays a crucial role in preventing the spread of cancer. The study found that replacing this gene in human metastatic cancer cells can suppress their ability to metastasize, suggesting new therapeutic options for treating metastatic disease.
Researchers at UW-Madison have identified the PIPKI?661 enzyme as a promising target for preventing cancer cells from metastasizing. By inhibiting this enzyme, cancer cells' ability to migrate to other parts of the body can be blocked.
Researchers found that EZH2 expression was significantly higher in metastatic prostate cancer tissue compared to localized prostate cancer. A future test for high levels of EZH2 protein could serve as a red flag for physicians to identify men with the most aggressive form of the disease.
The University of Pittsburgh Cancer Institute has discovered three proteins present in liver tissue from colon cancer patients that are not found in normal liver tissue. The findings hold promise for developing a more sensitive tumor marker for early detection and predicting potential recurrence.
A research team led by Wake Forest and Johns Hopkins universities found that mutations in the MSR1 gene are associated with an increased risk of aggressive prostate cancer, particularly in African-American men. The study identified seven potentially important mutations of the MSR1 gene, including one that leads to rapid metastasis.
A review highlights the association between excess body weight and increased cancer risk, particularly in colon, breast, endometrium, oesophagus, and kidney. The study suggests that alterations in hormone metabolism may play a role in this link, emphasizing the importance of weight management for cancer prevention.
Researchers engineered a virus to target prostate-specific antigen, appearing as 'hot spots' in primary tumors and distant metastases. This method could deliver toxic treatments directly to prostate cancer cells, killing them while sparing surrounding healthy tissue.
A new radium isotope, radium223, has shown promise in treating skeletal metastases with less damage to bone marrow compared to traditional treatments. The isotope is incorporated into skeletal tissue via osteoclasts and emits radiation that kills cancer cells, providing pain relief and potentially improving quality of life.
Cancer cells invading blood vessels and lymph vessels allows them to grow anew in other parts of the body. NFAT protein is found to be contributing to aggressive behavior of cancer cells and associated with alpha 6 beta 4 integrin, a hallmark of metastatic tumors.
A test to detect the RhoC protein has shown promising early results, detecting invasive cancers with high specificity and identifying tiny tumors that have already metastasized. The study aims to identify early-stage cancer that could be vulnerable to aggressive treatment, potentially leading to improved patient outcomes.
Researchers have discovered four biochemical markers that can predict a woman's likelihood of developing metastatic disease in node-negative breast cancer. These markers, including p53, E-cadherin, and nm23H1, were found to be significant predictors of outcome, allowing for more accurate identification of patients at risk. This breakth...
Researchers have developed new markers capable of detecting minute numbers of cancer cells in blood, using three genes shown to be over-expressed in invasive breast cancer. The markers' sensitivity and specificity are greatly enhanced when used in combination.
Researchers suggest that biopsying internal mammary sentinel nodes can help doctors detect more accurate spread of breast cancer, leading to better treatment options. The procedure involves a small cut through the breast bone to remove the node, and has been found to be successful in 65% of cases.
Researchers discovered that COX-2 inhibition can prevent Barrett's esophageal cell proliferation and that p16 mutations may impair melanocyte senescence. Additionally, a common polymorphism in the GH1 gene may be associated with a decreased risk of colorectal cancer.
A study published in The Journal of Nuclear Medicine found that PET imaging was more accurate than conventional imaging in detecting recurrent breast cancer. PET correctly predicted the outcome in 80% of cases vs. 20% for conventional imaging, with a higher sensitivity and specificity.
Researchers have discovered a promising new target for cancer chemotherapy by blocking cell uptake of polyamines with a heparan sulfate inhibitor. This approach, combined with a well-known anti-parasitic drug, shows great promise in reducing tumor formation.
A new study from Duke University challenges the common assumption that small lung tumors represent early-stage cancers. Despite their small size, these tumors can still be advanced stages of cancer with a high chance of spreading.
A Phase II trial found an overall response rate of 78% with the combination, compared to 75% with single-agent treatment. The addition of Navelbine to Herceptin was well-tolerated, with no severe side effects reported.
A genetic vaccine developed by the University of Nebraska Medical Center has shown promising results in mice studies, combining DNA and adenovirus to deliver a tumor suppressor factor. The vaccine improved survival rates up to 40% in mice with metastatic breast cancer.
Researchers at Rotterdam University Hospital develop genetically engineered T cells to target kidney cancer. The therapy combines the cellular immune system with the humoral immune system, offering a promising treatment option for patients with metastases.
Cancer patients' dietary needs vary according to disease stage, with underweight patients benefiting from fatty foods and those well-recovering advised on traditional healthy diets. The study found that nearly two-thirds of patients changed their eating habits since diagnosis, with most taking nutritional supplements.
A new study found that PET scans changed clinical management for 60% of women with recurrent breast cancer, including shifting from surgery to radiation therapy or medical treatment. The scan also significantly impacted disease staging, upstaging 28% and downstaging 8%, leading to more patients being classified as stage IV.
A team of researchers at Penn State's College of Medicine has isolated and characterized a gene, BRMS1, that plays a role in blocking tumor cells' ability to spread. The gene provides a target for developing therapies to keep cancer localized and may aid in proper diagnosis.
A Phase III study found that a combination of histamine dihydrochloride and lower doses of interleukin-2 improved overall survival, increased survival rates at 12, 18, and 24 months, and reduced time-to-disease-progression compared to IL-2 alone. The treatment was well-tolerated and had substantially less toxicity.
Researchers found two protein biomarkers, cIAP-1 and XIAP, that correlate with distant metastasis-free survival in prostate cancer patients. Elevated levels of these proteins were associated with a higher risk of relapse after radiation therapy.
A new treatment combination of paclitaxel and carboplatin has shown encouraging results in a clinical trial, achieving a 62% response rate and a projected 72% one-year survival rate. The treatment, which is compatible with prior anthracycline therapy, offers additional benefits for women with metastatic breast cancer.
A new test developed by USC scientists and colleagues can accurately detect hidden breast cancer cells in lymph nodes, improving the detection of metastases. This breakthrough enables customized treatments tailored to individual patients' characteristics, such as tumor size and hormone receptor status.
A new study developed a simple method to assess the risk of deadly metastatic cancer in men after prostate removal. The chart uses three common measures, including Gleason score and PSA doubling time, to pinpoint the risk for developing metastatic cancer.
A team of researchers at Duke University Medical Center has mapped a region of human chromosome 11 and identified a new gene, RRM1, that is believed to be responsible for the aggressive nature of lung cancer. The gene's role in DNA production and repair makes it a potential therapeutic target for improving treatment outcomes.
A study by Weizmann researchers suggests that a cell-suicide gene called DAP-kinase can prevent metastasis in cancer. The gene's proper functioning is essential for cells to die during different stages of metastasis, and its loss or malfunction can lead to unwanted cell proliferation and tumor development.
Researchers at Penn State have discovered a new gene called KiSS-1 that suppresses the metastasis of melanoma in laboratory mice. The gene, located on chromosome 1, reduces the spread of melanoma by at least 50 percent of the time and may be the most potent gene to block or suppress metastasis in human cancer.
Researchers at UCLA's Jonsson Comprehensive Cancer Center are testing the safety and effectiveness of TNP-470, an experimental drug that prevents tumor growth by blocking the formation of new blood vessels. The study aims to reduce tumor size and prevent cancer spread in patients with metastatic breast cancer.